NCCN Clinical Practice Guidelines in Oncology on Adult Cancer Pain
NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.
Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.
Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).
Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines™ is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.
© National Comprehensive Cancer Network, Inc. 2010, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
Disclosures for the NCCN Guidelines Panel for Adult Cancer Pain
At the beginning of each NCCN Guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.
Individual disclosures for the NCCN Guidelines on Adult Cancer Pain panel members can be found on page 1086. (The most recent version of these guidelines and accompanying disclosures, including levels of compensation, are available on the NCCN Web site at www.NCCN.org.)
These guidelines are also available on the Internet. For the latest update, please visit www.NCCN.org.
Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl1986;3(Supp 1):226.
CohenMZEasleyMKEllisC. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage2003;25:519–527.
SvendsenKBAndersenSArnasonS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain2005;9:195–206.
MartinLAHagenNA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage1997;14:99–117.
StjernswardJColleauSMVentafriddaV. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage1996;12:65–72.
HicksCLvon BaeyerCLSpaffordPA. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain2001;93:173–183.
SerlinRCMendozaTRNakamuraY. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain1995;61:277–284.
SoetengaDFrankJPellinoTA. Assessment of the validity and reliability of the University of Wisconsin Children's Hospital Pain scale for Preverbal and Nonverbal Children. Pediatr Nurs1999;25:670–676.
EzenwaMOAmeringerSWardSESerlinRC. Racial and ethnic disparities in pain management in the United States. J Nurs Scholarsh2006;38:225–233.
MercadanteSLBerchovichMCasuccioA. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care2007;24:13–19.
KlepstadPKaasaSBorchgrevinkPC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol2000;55:713–719.
KlepstadPKaasaSSkaugeMBorchgrevinkPC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand2000;44:656–664.
KornickCASantiago-PalmaJKhojainovaNL. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer2001;92:3056–3061.
TiseoPJThalerHTLapinJ. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain1995;61:47–54.
PortenoyRKFoleyKMStulmanJ. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991;47:13–19.
BarkinRLBarkinSJBarkinDS. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. Am J Ther2006;13:534–542.
AubertRStanekEJYaoJ. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract CRA508.
DezentjeVVan BlijderveenNJGelderblomH. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study [abstract]. J Clin Oncol2009;27(Suppl 1):Abstract CRA509.
McNicolEHorowicz-MehlerNFiskRA. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain2003;4:231–256.
MorylNCarverAFoleyKM. Pain and palliation. In: HollandJFFreiE eds. Cancer Medicine. Vol. I7. Hamilton, ON: BC Decker Inc; 2006:1113–1124.
MorylNObbensEAOzigboOHKrisMG. Analgesic effect of gefitinib in the treatment of non-small cell lung cancer. J Support Oncol2006;4:111.
BoettgerSBreitbartW. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care2005;3:227–237.
BreitbartWMarottaRPlattMM. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry1996;153:231–237.
BrueraEBelzileMNeumannC. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage2000;19:427–435.
MarinellaMA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson's disease. South Med J1997;90:1023–1026.
TarcatuDTamasdanCMorylNObbensE. Are we still scratching the surface? A case of intractable pruritus following systemic opioid analgesia. J Opioid Manag2007;3:167–170.
HawleyPHByeonJJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med2008;11:575–581.
MercadanteSArcuriEFerreraP. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage2005;30:485–491.
GreenbergHSTarenJEnsmingerWDDoanK. Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain. J Neurosurg1982;57:360–364.
JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:30–39.
StocklerMVardyJPillaiAWarrD. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol2004;22:3389–3394.